Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.51+0.22 (+1.66%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Trevi Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Trevi Therapeutics's total assets was $330.52M at Jun 30, 2026. For fiscal 2025 it was $193.44M, up 74.4% from the year before. The highest annual figure on record is $193.44M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.44M | +74.4% |
| FY2024 | Dec 31, 2024 | $110.90M | +24.0% |
| FY2023 | Dec 31, 2023 | $89.40M | -27.3% |
| FY2022 | Dec 31, 2022 | $123.02M | +219.7% |
| FY2021 | Dec 31, 2021 | $38.48M | -18.4% |
| FY2020 | Dec 31, 2020 | $47.13M | -21.4% |
| FY2019 | Dec 31, 2019 | $60.00M | +470.0% |
| FY2018 | Dec 31, 2018 | $10.53M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $330.52M | +58.6% |
| Q1 FY2026 | Mar 31, 2026 | $179.61M | +67.8% |
| Q4 FY2025 | Dec 31, 2025 | $193.44M | +74.4% |
| Q3 FY2025 | Sep 30, 2025 | $199.36M | +189.3% |
| Q2 FY2025 | Jun 30, 2025 | $208.34M | +182.3% |
| Q1 FY2025 | Mar 31, 2025 | $107.00M | +36.2% |
| Q4 FY2024 | Dec 31, 2024 | $110.90M | +24.0% |
| Q3 FY2024 | Sep 30, 2024 | $68.91M | -28.1% |
| Q2 FY2024 | Jun 30, 2024 | $73.81M | -26.9% |
| Q1 FY2024 | Mar 31, 2024 | $78.56M | -32.4% |
| Q4 FY2023 | Dec 31, 2023 | $89.40M | -27.3% |
| Q3 FY2023 | Sep 30, 2023 | $95.90M | -25.3% |
| Q2 FY2023 | Jun 30, 2023 | $100.98M | +24.0% |
| Q1 FY2023 | Mar 31, 2023 | $116.21M | +282.4% |
| Q4 FY2022 | Dec 31, 2022 | $123.02M | +219.7% |
| Q3 FY2022 | Sep 30, 2022 | $128.36M | +306.3% |
| Q2 FY2022 | Jun 30, 2022 | $81.41M | +108.0% |
| Q1 FY2022 | Mar 31, 2022 | $30.39M | -29.1% |
| Q4 FY2021 | Dec 31, 2021 | $38.48M | -18.4% |
| Q3 FY2021 | Sep 30, 2021 | $31.60M | -43.5% |
| Q2 FY2021 | Jun 30, 2021 | $39.15M | -16.7% |
| Q1 FY2021 | Mar 31, 2021 | $42.86M | -21.0% |
| Q4 FY2020 | Dec 31, 2020 | $47.13M | -21.4% |
| Q3 FY2020 | Sep 30, 2020 | $55.88M | -15.4% |
| Q2 FY2020 | Jun 30, 2020 | $47.01M | -37.4% |
| Q1 FY2020 | Mar 31, 2020 | $54.24M | +215.6% |
| Q4 FY2019 | Dec 31, 2019 | $60.00M | +470.0% |
| Q3 FY2019 | Sep 30, 2019 | $66.02M | – |
| Q2 FY2019 | Jun 30, 2019 | $75.12M | – |
| Q1 FY2019 | Mar 31, 2019 | $17.19M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.53M | – |
See a number that looks wrong?